| Market Cap | 1.13M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -5.78M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -23.00% |
| Sales | 335.15k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -76.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -94.00% |
| Recommedations | - | Quick Ratio | 0.18 | Shares Outstanding | 122.02M | 52W Low Chg | 300.00% |
| Insider Own | 83.45% | ROA | -599.91% | Shares Float | 4.40M | Beta | 18.55 |
| Inst Own | - | ROE | - | Shares Shorted/Prior | -/- | Price | 0.00040 |
| Gross Margin | 72.45% | Profit Margin | - | Avg. Volume | 87,925 | Target Price | - |
| Oper. Margin | -1,141.43% | Earnings Date | - | Volume | 360,000 | Change | 0.00% |
Rafina Innovations Inc. engages in the research, development, commercialization, and marketing of medical technologies. It operates through two segments, Clinics and Technology. The company also operates prosthetics and orthotics, and diabetic foot total rehabilitation clinics in Southern Europe, the Middle East, and North Africa. In addition, it is involved in the research, development, and commercialization of medical devices, methods, and products in the fields of prosthetics, orthotics, rehabilitation, bioengineering, mobility, diabetes, diabetic foot, tissue mechanics, ultrasonics, medical signal processing and analysis, medical technology, orthopedics, and robotic surgery; and licensing of its proprietary technologies. The company was formerly known as HCi Viocare and changed its name to Rafina Innovations Inc. in July 2018. Rafina Innovations Inc. was founded in 2007 and is based in Glasgow, the United Kingdom.